Raloxifene in Breast Cancer Survivors: Protective or Risky?
Raloxifene is often prescribed to reduce the risk of invasive breast cancer in postmenopausal women, including survivors. It acts as a selective estrogen receptor modulator (SERM), blocking estrogen’s effects on breast tissue while mimicking its bone-protective benefits. For breast cancer survivors, raloxifene can offer protective advantages by lowering recurrence risk, especially for hormone receptor-positive cancers. However, it may increase the risk of blood clots or stroke in some individuals.https://www.dosepharmacy.com/ralista-60mg-tablet
Raloxifene is often prescribed to reduce the risk of invasive breast cancer in postmenopausal women, including survivors. It acts as a selective estrogen receptor modulator (SERM), blocking estrogen’s effects on breast tissue while mimicking its bone-protective benefits. For breast cancer survivors, raloxifene can offer protective advantages by lowering recurrence risk, especially for hormone receptor-positive cancers. However, it may increase the risk of blood clots or stroke in some individuals.https://www.dosepharmacy.com/ralista-60mg-tablet
Raloxifene in Breast Cancer Survivors: Protective or Risky?
Raloxifene is often prescribed to reduce the risk of invasive breast cancer in postmenopausal women, including survivors. It acts as a selective estrogen receptor modulator (SERM), blocking estrogen’s effects on breast tissue while mimicking its bone-protective benefits. For breast cancer survivors, raloxifene can offer protective advantages by lowering recurrence risk, especially for hormone receptor-positive cancers. However, it may increase the risk of blood clots or stroke in some individuals.https://www.dosepharmacy.com/ralista-60mg-tablet
0 Σχόλια
0 Μοιράστηκε
1χλμ. Views
0 Προεπισκόπηση